TMCnet News
RxGen to Present Alzheimer's Disease APP/Abeta Cellular and Animal Models at the Society for Neuroscience's 49th Annual MeetingNEW HAVEN, Conn., Oct. 14, 2019 (GLOBE NEWSWIRE) -- RxGen, a preclinical translational research company, will be presenting a poster highlighting its progress in advancing preclinical models of Alzheimer’s disease (AD) to better predict clinical outcomes during the Society for Neuroscience (SfN) 49th Annual Meeting in Chicago from October 19-23, 2019. One of the primary challenges in drug development is the inability of preclinical models to reliably predict clinical outcomes. This lack of translation has been especially evident and costly in the pursuit of AD therapeutics given the complexity of the disease’s pathophysiology. RxGen’s focus and expertise in nonhuman primate (NHP) translational test systems offers a significant advantage in the discovery and development of new potential therapeutics for this significant unmet clinical need, as NHPs share critical homology to humans in pathophysiology and anatomy relevant to AD modeling. Details of the poster presentation are as follows:
About RxGen (www.rx-gen.com) RxGen: Media: |